Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis

Clinical and Translational Oncology

Volumn 18, Issue 6, 2016, Pages 641-649

  Tian, R H ^a   Zhang, Y G ^b   Wu, Z ^a   Liu, X ^a   Yang, J W ^a   Ji, H L ^a  

^a NANTONG UNIVERSITY   (China)

^b The Shouguang People s Hospital   (China)

Author keywords

Diabetes; Lung cancer; Meta analysis; Metformin; Prognosis

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG EFFECT; HUMAN; LUNG CANCER; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SAMPLE SIZE; SMALL CELL LUNG CANCER; COMPLICATION; DIABETES MELLITUS, TYPE 2; LUNG TUMOR; MORTALITY; PROGNOSIS;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LUNG NEOPLASMS; METFORMIN; PROGNOSIS;

EID: 84944707681     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-015-1412-x     Document Type: Article

References (31)

1. Richardson LC, Pollack LA. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol. 2005;2:48–53. doi:10.1038/ncponc0062.
2. Noto H, Tsujimoto T, Sasazuki T, Noda M. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Endocr Pract. 2011;17:616–28. doi:10.4158/ep10357.ra.
3. Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev. 2015;95:727–48. doi:10.1152/physrev.00030.2014.
4. Wu L, Wang Z, Zhu J, Murad AL, Prokop LJ, Murad MH. Nut consumption and risk of cancer and type 2 diabetes: a systematic review and meta-analysis. Nutr Rev. 2015;73:409–25. doi:10.1093/nutrit/nuv006.
5. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.21262.
6. Aljada A, Mousa SA. Metformin and neoplasia: implications and indications. Pharmacol Ther. 2012;133:108–15. doi:10.1016/j.pharmthera.2011.09.004.
7. Smiechowski BB, Azoulay L, Yin H, Pollak MN, Suissa S. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care. 2013;36:124–9. doi:10.2337/dc12-0740.
8. Del Barco S, Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, et al. Metformin: multi-faceted protection against cancer. Oncotarget. 2011;2:896–917.
9. Mazzone PJ, Rai H, Beukemann M, Xu M, Jain A, Sasidhar M. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer. 2012;12:410. doi:10.1186/1471-2407-12-410.
10. Lai SW, Liao KF, Chen PC, Tsai PY, Hsieh DP, Chen CC. Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. Clin Lung Cancer. 2012;13:143–8. doi:10.1016/j.cllc.2011.10.002.
11. Bodmer M, Becker C, Jick SS, Meier CR. Metformin does not alter the risk of lung cancer: a case-control analysis. Lung Cancer. 2012;78:133–7. doi:10.1016/j.lungcan.2012.08.010.
12. Xu T, Liang G, Yang L, Zhang F. Prognosis of small cell lung cancer patients with diabetes treated with metformin. Clin Transl Oncol. 2015;. doi:10.1007/s12094-015-1311-1.
13. Lin JJ, Gallagher EJ, Sigel K, Mhango G, Galsky MD, Smith CB, et al. Survival of patients with stage IV lung cancer with diabetes treated with metformin. Am J Respir Crit Care Med. 2015;191:448–54. doi:10.1164/rccm.201407-1395OC.
14. Wells GA, Shea B, O’Connel D, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60. doi:10.1136/bmj.327.7414.557.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
17. Copas J, Shi JQ. Meta-analysis, funnel plots and sensitivity analysis. Biostatistics. 2000;1:247–62. doi:10.1093/biostatistics/1.3.247.
18. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–12. doi:10.1016/j.jclinepi.2009.06.005.
19. Kong F, Gao F, Liu H, Chen L, Zheng R, Yu J, et al. Metformin use improves the survival of diabetic combined small-cell lung cancer patients. Tumour Biol. 2015;. doi:10.1007/s13277-015-3549-1.
20. Ahmed I, Ferro A, Cohler A, Langenfeld J, Surakanti SG, Aisner J, et al. Impact of metformin use on survival in locally-advanced, inoperable non-small cell lung cancer treated with definitive chemoradiation. J Thorac Dis. 2015;7:346–55. doi:10.3978/j.issn.2072-1439.2014.12.32.
21. Xu H, Aldrich MC, Chen Q, Liu H, Peterson NB, Dai Q, et al. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc. 2015;22:179–91. doi:10.1136/amiajnl-2014-002649.
22. Johnson JA, Gale EA. Diabetes, insulin use, and cancer risk: are observational studies part of the solution-or part of the problem? Diabetes. 2010;59:1129–31. doi:10.2337/db10-0334.
23. Yang X, Ko GT, So WY, Ma RC, Yu LW, Kong AP, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes. 2010;59:1254–60. doi:10.2337/db09-1371.
24. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275:223–8.
25. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348(Pt 3):607–14.
26. Bao B, Wang Z, Li Y, Kong D, Ali S, Banerjee S, et al. The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim Biophys Acta. 2011;1815:135–46. doi:10.1016/j.bbcan.2010.11.003.
27. Zannella VE, Dal Pra A, Muaddi H, McKee TD, Stapleton S, Sykes J, et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res. 2013;19:6741–50. doi:10.1158/1078-0432.ccr-13-1787.
28. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci USA. 2015;112:1809–14. doi:10.1073/pnas.1417636112.
29. Bao B, Azmi AS, Ali S, Zaiem F, Sarkar FH. Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers. Ann Transl Med. 2014;2:59. doi:10.3978/j.issn.2305-5839.2014.06.05.
30. Kim JS, Kim ES, Liu D, Lee JJ, Behrens C, Lippman SM, et al. Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer. Oncotarget. 2015;6:16746–56.
31. Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, et al. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer. 2012;118:2454–65. doi:10.1002/cncr.26492.